Document:

<PAGE>   1
                                                                   EXHIBIT 10.02

           CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this
               document have been omitted and are marked with the
           notation, "*Confidential Treatment Requested." A complete
        copy has been filed with the Securities and Exchange Commission.

                                HEMOTECH AND CIT
                   AMENDED AND RESTATED ALLOSTERIC MODIFIERS
                                       OF
                              HEMOGLOBIN AGREEMENT

This Amended and Restated Agreement is made between HemoTech Sciences Inc.
(Hemotech), a corporation organized under the laws of Virginia, and the Center
for Innovative Technology (CIT), a corporation organized under the laws of the
Commonwealth of Virginia.

1.   INTRODUCTION

     1.1 CIT possesses a disclosure of technology developed by Donald J.
Abraham et al. and related to allosteric modifiers of hemoglobin (CIT Case Nos.
116, 169, 214A, and 214B). This technology is described more fully in U.S.
Patent 5,049,695, U.S. Patent 5,122,539, U.S. Patent 5,248,785, U.S. Patent
5,250,701 and U.S. Patent Application Nos. 08/101,501; 08/006,246; 07/623346;
and 07/722,382. Hereafter, this technology, together with any technology
developed pursuant to the research described in Sections 3 and 10.3 hereof, is
referred to as the "Technology". Hereafter, "Licensed Patent Rights" shall mean
the foregoing patents and patent applications, any other patent applications
relating to the Technology, all applications filed outside of the United States
and all issued patents resulting therefrom or relating thereto as well as all
substitutions, extensions, reissues, renewals, re-examinations, continuations
and continuations-in-part and their foreign counterparts. The inventors of the
Technology have assigned their interests in the Technology to the Virginia
Commonwealth University (VCU), which has assigned its interest to CIT. CIT has
applied for, or plans to apply for, patent protections on all or a portion of
the Technology.

     1.2 CIT and VCU desire that the Technology be used in the public interest
and made available to the public quickly and efficiently.

     1.3 HemoTech is able to develop and bring to market the Technology. It
desires to obtain license rights set forth in this agreement.

2.   LICENSE

     2.1 CIT grants to HemoTech an exclusive, worldwide license to practice,
develop and use the Technology and the Licensed Patent Rights and to make, have
made, use and sell products which incorporate the Technology and/or the
Licensed Patent Rights. Hereafter, the term "Licensed Products" means products
which (a) incorporate the Technology and/or the Licensed Patent Rights and (b)
would infringe a Valid Claim (as such term is hereinafter defined) of Licensed
Patent Rights in any country in which such products are made or sold if not for
the license contained herein. Hereafter, the term "Valid Claim" means, in a
particular country,
<PAGE>   2
                                      -2-

a claim of CIT in an issued, unexpired patent within the Licensed Patent
Rights, which has not been held within such country to be unenforceable,
unpatentable or invalid by a final decision of a court or other governmental
body of competent jurisdiction, which is unappealable or unappealed within the
time allowed for appeal, which has not been rendered unenforceable through
disclaimer or otherwise, and which has not been lost within such country
through an interference proceeding.

     2.2 In return for the license to Technology granted by CIT HemoTech shall
pay to CIT [ * ] by January 15, 1994, and [ * ] by September 30, 1994.

     2.3 In return for the license granted by CIT HemoTech shall pay to CIT a
running royalty of [*]% of its (worldwide) net revenues arising from sales of
Licensed Products produced in Virginia and [*]% of its (worldwide) net revenues
from Licensed Products which are not produced in Virginia. The term "produced in
Virginia" has the meaning set forth in Section 8. "Net Revenues" means
HemoTech's gross revenues from sales of Licensed Products less the sum of the
following: A) sales, tariff duties and/or use taxes directly imposed and with
reference to particular sales; B) outbound transportation and insurance; C)
amounts representing uncollectible billings; and D) amounts allowed or credited
on returns. Revenues shall be determined on an accrual basis in accordance with
generally accepted accounting principles.

     2.4 When a Licensed Product is disposed of other than by sale, e.g.
leased, net revenues shall include the selling price at which products of
similar kind and quality, sold in similar quantities, are currently being
offered for sale by HemoTech (or other manufacturers if HemoTech is not
currently offering such Licensed Products of similar kind and quality for sale).

     2.5 In the event HemoTech provides any service using a Licensed Product,
rather than selling such Licensed Product, HemoTech shall include in net
revenues an amount equal to the selling price at which such Licensed Products
would be sold to a third party by HemoTech in an arms-length transaction. In
the event HemoTech makes use of a method which is part of the Technology
HemoTech shall include in net revenues an amount equal to the selling price of
the Licensed Products used to implement the method.

     2.6 Within 30 days of execution of this agreement HemoTech shall issue to
CIT 400,000 shares of common stock, which shall represent twenty percent (20%)
of the aggregate of (a) shares of HemoTech's capital stock then outstanding,
(b) shares of HemoTech's capital stock then subject to securities exercisable
for or exchangeable for capital stock (other than securities issued in

*CONFIDENTIAL TREATMENT
       REQUESTED
<PAGE>   3

                                        - 3 -

connection with the financing contemplated by Section 2.8 of this agreement)
and (c) shares of HemoTech's capital stock then subject to issuance pursuant to
written agreement (other than agreements entered into in connection with the
financing contemplated by Section 2.8 of this Agreement); provided, however,
that HemoTech shall not be obligated to issue such shares if CIT terminates
this agreement pursuant to section 2.8.  Notwithstanding anything to the
contrary contained in this Section 2.6, (a) upon issuance of such common stock
and the consummation of the financing contemplated by Section 2.8 of this
agreement, CIT shall have no preemptive or preferential right to purchase or
subscribe for any shares of any class of capital stock of the Company whether
now or hereafter authorized; any warrants, rights, or options to purchase any
such shares; any securities or obligations convertible into such shares or into
warrants, rights or options to purchase any such shares; or any other securities
which are exercisable for or exchangeable for such shares (collectively, the
"Securities"); and (b) CIT's ownership interest in HemoTech will be diluted by
(i) the issuance of capital stock in connection with such financing; and (ii)
all issuances of capital stock occurring on or after the date of such financing.

     2.7  HemoTech shall deliver to CIT a business plan within ten (10) days of
the execution of this agreement.

     2.8  HemoTech shall by January 15, 1994, arrange financing for its
operation such that HemoTech has received at least $700,000 by that date for
conduct of its activities pursuant to a transaction in the form described in
the Terms and Conditions of Proposed Equity Investment by the Partners of
MedVest, Inc. dated November 1, 1993.  Breach of this provision shall be
considered material breach of this agreement and entitle CIT to terminate this
license.

     2.9   HemoTech shall, within thirty (30) days from the end of each
calendar quarter, deliver to CIT a report giving such particulars of the
business conducted by HemoTech during the preceding three month period under
this license as are pertinent to royalty accounting under this agreement.
Simultaneously with the delivery of each calendar quarterly report, HemoTech
shall pay to CIT royalties due and payable for the period covered by such
report under this agreement.  If no royalties are due, it shall be so reported.

3.   FUNDING OF RESEARCH

HemoTech shall sponsor research at VCU relating to the Technology.  The
research shall be sponsored under one or more renewable agreements providing
for the payment by HemoTech of [ * ] by December 31, 1995. The terms of such
research agreement(s) shall be those contained in the standard research
agreement used by VCU,

*CONFIDENTIAL TREATMENT
       REQUESTED
<PAGE>   4

                                      -4-

except that the research agreement shall provide that inventions made in the
course of the research which are included in any claim of a U.S. patent licensed
to HemoTech under this agreement will be licensed to HemoTech as part of the
Technology licensed under this agreement. If VCU declines to enter into
agreement(s) containing such terms, HemoTech shall not be obligated by this
agreement to sponsor such research.

4.   SUBLICENSES

HemoTech shall have the right to grant sublicenses, all of which shall be
subordinate to this agreement. HemoTech shall pay to CIT royalties on products
produced by sublicensees as if HemoTech had produced the products itself.
HemoTech shall also provide to CIT reports on the activities of each sublicensee
which reports shall contain the name of the sublicensee and the same information
as is required of HemoTech under this agreement.

5.   PATENT PROSECUTION

     5.1  CIT shall file, prosecute, and maintain during the term of this
agreement intellectual property protection for the Technology in the United
States, Japan, Canada, and the countries of the European Community. The filing,
prosecution, and maintenance of intellectual property protection shall be the
primary responsibility of CIT. However, HemoTech shall have reasonable
opportunities to advise CIT and shall cooperate with CIT in such filing,
prosecution, and maintenance. Prior to taking any action for which the cost is
estimated to be in excess of $1,000, CIT shall seek the approval of HemoTech. If
HemoTech approves then it shall be liable for the costs incurred, whether such
costs are greater than or less than the estimate. If HemoTech does not approve
of the action then CIT may pursue the action at its own expense or may decide to
not pursue the action.

     5.2 HemoTech shall reimburse CIT for all costs incurred by CIT after July
1, 1993 related to obtaining and maintaining intellectual property protection
for the Technology. Such costs include legal fees, fees of experts, such as
consulting engineers, travel costs, drafting and printing costs, and other
directly related costs. Such costs do not include any amounts for time devoted
by CIT employees or CIT's supervision of the patenting process. CIT shall
invoice HemoTech for costs incurred. HemoTech shall reimburse CIT for such costs
within thirty (30) days of receipt of the invoice.

6.   SECURITY INTEREST

HemoTech grants to CIT a security interest in this agreement, in every
sublicense granted by HemoTech, and in all payments due under
<PAGE>   5
                                      -5-

any such sublicense. This security interest secures HemoTech's performance of
its obligations under this agreement. HemoTech shall cooperate with CIT in
perfecting this security interest, including the execution of any necessary
financing statements.

7.   TERMINATION

     7.1 This license shall expire on the date upon which the last U.S. patent
on the Technology expires. If no U.S. patent is granted then this license shall
expire on December 31, 2009.

     7.2 CIT, at its option, may terminate this license upon notice to HemoTech
for material breach of this agreement. Such termination shall not be CIT's
exclusive remedy for breach and HemoTech shall remain liable for damages
arising from its breach after such termination. Material breach includes, but
is not limited to, failure to pay royalties when due and failure of HemoTech to
diligently pursue introduction of the Technology into the market and sales of
Licensed Products. It is envisaged by the parties that a failure to diligently
pursue introduction of the Technology and sales may occur if HemoTech is
involved in a proceeding for the reorganization of HemoTech and, consequently,
is unable to devote sufficient resources to the work.

8.   OPERATIONS TO BE IN VIRGINIA

HemoTech shall locate its headquarters in Virginia. All Licensed Products which
are sold in the United States shall be produced in Virginia. "Produced in
Virginia" means that at least 50% of the cost of physically making each
saleable unit of product shall arise from work performed in Virginia, except
that if 50% of the cost of physically making the products cannot occur in
Virginia due to the excessive cost of Virginia operations, then only those
operations which can be economically performed in Virginia shall be performed
in Virginia. A manufacturing operation shall be considered able to  be
economically performed in Virginia if the cost of performing operation in
Virginia is no more than 120% of the cost of performing the operation elsewhere.

9.   CONFIDENTIALITY

     9.1 Except to the extent expressly authorized by this agreement, the
parties agree that, for the term of this agreement and for five years
thereafter, the receiving party shall keep completely confidential and shall
not, without the prior written consent of the disclosing party, publish or
otherwise disclose (other than to officers, directors or employees, agents or
consultants on a need-to-know basis and subject to an obligation of
confidentiality substantially similar to the obligation contained
herein) or use for any purpose except as provided in this

* CONFIDENTIAL TREATMENT
        REQUESTED
<PAGE>   6
                                      -6-

agreement any information furnished to it by the other party pursuant to this
agreement (the "Confidential Information"), except to the extent that it can be
established by the receiving party by competent proof that such confidential
information:

          (a) was already known to the receiving party, other than under an
              obligation of confidentiality, at the time of disclosure by the
              other party, as evidenced by written records;

          (b) was generally available to the public or otherwise part of the
              public domain at the time of its disclosure to the receiving
              party;

          (c) became generally available to the public or otherwise part of the
              public domain after its disclosure and other than through any act
              or omission of the receiving party in breach of this agreement;

          (d) was subsequently lawfully disclosed to the receiving party by a
              third party without to the receiving party; or

          (e) was subsequently independently developed by the receiving party,
              as evidenced by written records (provided that the Technology
              shall not be deemed to fall within this exception).

     9.2 Each party may disclose Confidential Information to the extent such
disclosure is reasonably necessary in prosecuting or defending litigation,
filing patent applications, complying with applicable governmental regulations,
conducting clinical trials or for any other purpose under this agreement;
provided that, if a party proposes to make any such disclosure it will give
reasonable advance notice to the other party of such disclosure and, save to
the extent inappropriate in the case of patent applications, will use all
reasonable efforts to secure confidential treatment of such information
required to be disclosed.

     9.3 The parties acknowledge and agree that any breach by a party of the
covenants set forth herein, including without limitation those in Section 9.1,
will likely result in irreparable harm to the non-breaching party for which
monetary damages will be inadequate compensation. The parties therefore agree
that in the event of a breach or threatened breach of any provision of this
agreement, the non-breaching party shall be entitled to appropriate injunctive
relief, including without limitation temporary or permanent injunctions or
restraining orders. The foregoing remedies shall be in addition to and not to
the exclusion of any

<PAGE>   7
                                        - 7 -

other remedies which the non-breaching party may have at law or in equity.

10.  MISCELLANEOUS PROVISIONS

     10.1 HemoTech shall keep records containing all particulars which may be
necessary for the purpose of showing the royalty payable to CIT.  These
records shall be open at all reasonable times for three (3) years following the
end of the calendar year to which they pertain to the inspection of an
independent certified public accounting firm retained by CIT at its sole
expense for the purpose of verifying HemoTech's royalty reports.

     10.2 This agreement shall be construed, governed, interpreted and applied
in accordance with the internal laws of the Commonwealth of Virginia, U.S.A.
except that questions affecting the validity, construction and effect of any
patent shall be determined by the laws of the country in which the patent was
granted.

     10.3 Subject to Section 1.1 hereof, CIT and VCU retain the right to make
use of the Technology for the purpose of research and not for commercial
development.

     10.4 HemoTech agrees to mark Licensed Products employing the Technology
with appropriate patent notices.

     10.5 In the event that either party hereto learns of any alleged
infringement of the Technology and/or the Licensed Patent Rights, such party
shall promptly notify the other in writing of such alleged infringement and of
any available evidence thereof. HemoTech shall have the right, but not the
obligation, to prosecute any and all infringements of any Technology and/or
Licensed Patent Rights to which HemoTech obtains rights hereunder, and to defend
all charges of infringement arising as a result of said Technology and/or
Licensed Patent Rights and to enter all settlements, judgements or other
arrangements respecting the same all at its own expense.  CIT shall permit any
action to be brought in its name, but only if required by law. HemoTech shall
hold CIT harmless from any cost, expense or liability respecting all charges of
infringement involving the Technology and/or Licensed Patent Rights brought by
HemoTech against third parties.  Any damages or other recovery from such
infringement actions shall be retained by HemoTech and HemoTech shall have no
obligation to make any payments to CIT except as expressly provided herein.
HemoTech shall determine whether or not it will prosecute any such infringement
action within 90 days of learning of the infringement. In the event HemoTech
determines not to prosecute any such infringement, HemoTech shall so notify CIT
within such 90-day period and thereafter CIT shall have the right to prosecute
such infringement

<PAGE>   8
                                      -8-

on its own behalf and its own expense and retain any damages or other recovery.

     10.6 If the Technology was developed with funds provided by the United
States, this agreement is subject to all applicable laws, regulations, and the
terms of any agreement under which funds were provided. This includes any
rights of the United States to use the Technology for governmental purposes,
any limits on the place of manufacture of products using the Technology, and
any obligations to make products based on the Technology available within a
reasonable time. These government rights are set forth at 35 USC Section 203 and
Section 204 and other locations. These provisions are incorporated in this
agreement by reference and the exercise of these rights by the United States
shall not constitute breach of this agreement.

     10.7 All payments shall be made in United States dollars. Any currency
conversion required shall be made at the exchange rate published in The Wall
Street Journal on the last day of the calendar quarter for which the payment is
made.

     10.8 Any unpaid amounts due hereunder shall bear interest at 2.5% over the
prime rate as published in The Wall Street Journal, compounded daily until
paid. This provision does not excuse any failure to pay and does not limit any
remedies for breach. In the event of breach of this agreement the breaching
party shall pay to the non-breaching party all costs, including attorney's
fees, of enforcing this agreement.

     10.9 Neither CIT, nor the investors, nor any Virginia university or other
agency of the Commonwealth of Virginia make any representations as to
patentability or protectability, validity, enforceability, freedom of the
Technology from infringement of the rights of others, likelihood of successfully
converting the Technology into commercial products or whether or not the
Technology is satisfactory for the purposes intended. CIT has no knowledge of
(a) any adversely held patent of any other person relating to the Technology or
(b) any basis for any such charge or claim. CIT has all right, title and
interest in the Licensed Patent Rights and the Technology. The inventors of the
Technology have assigned their interests in the Technology to VCU, which has
assigned its interest to CIT. Attached hereto as Exhibit A are copies of all
documents evidencing and relating to the assignment to VCU and CIT of the
Technology and/or the Licensed Patent Rights.

     10.10 HemoTech warrants that every individual with a personal interest in
HemoTech, as that term is defined in the Virginia Conflict of Interest Act, has
complied with the terms of that act and that no violation of that act will
result from this agreement.
<PAGE>   9
                                      -9-

     10.11  For purposes of CIT's agreements with the university which has
assigned the Technology to CIT, the amounts received by CIT pursuant to this
agreement are designated as reimbursement for expenses of filing, prosecuting,
and maintaining the patent applications and patents related to the Technology.

     10.12  The parties hereto acknowledge that this instrument sets forth the
entire agreement of the parties as to the subject matter hereof and shall not be
modified except by the execution a written instrument signed by the parties.
<PAGE>   10
                                      -10-

ACCEPTED AND AGREED TO:

CENTER FOR INNOVATIVE TECHNOLOGY

By: /s/ LINWOOD HOLTON                                      1/12/94
    ------------------------------                -----------------------------
Name:   LINWOOD HOLTON                            Date
Title:  PRESIDENT

HEMOTECH SCIENCES INC.

By: /s/ DONALD J. ABRAHAM                               January 10, 1994
    ------------------------------                -----------------------------
Name:   Donald J. Abraham                         Date
Title:  President, HemoTech Sciences Inc.<PAGE>   1
           CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this
               document have been omitted and are marked with the
           notation, "*Confidential Treatment Requested." A complete
        copy has been filed with the Securities and Exchange Commission.

                                                                   EXHIBIT 10.03

                 AMENDMENT TO ALLOS THERAPEUTICS, INC. AND CIT
        AMENDED AND RESTATED ALLOSTERIC MODIFIERS OF HEMOGLOBIN AGREEMENT

          This agreement of amendment (Amendment) is entered into as of January
          17, 1995 by and between Allos Therapeutics, Inc. (Allos) and the
          Center for Innovative Technology (CIT), both corporations organized
          under the laws of the Commonwealth of Virginia.

1  Allos, formerly Hemotech Sciences, Inc., and CIT entered into an agreement on
or about January 10, 1994, entitled Hemotech and CIT - Amended and Restated
Allosteric Modifiers of Hemoglobin Agreement (hereinafter called the Agreement).

2  Allos and CIT wish to amend the agreement as set forth in this Amendment in
order to (1) modify Section 3, Funding of Research, of the Agreement related to
inventions made in the course of Allos funded research and (2) to include two
(2) new disclosures of technology developed by Donald J. Abraham et al. related
to Allosteric modifiers of Hemoglobin.

2.1 In the third sentence of Paragraph 3, Funding of Research, of the Agreement,
which begins, "The terms of such research agreement..." strike the words
"...which are included in any claim of a U.S. Patent..." and in place of these
words insert "...funded by Allos and related to Allosteric Modifiers of
Hemoglobin..." The revised Paragraph 3 as amended herein shall read: Allos shall
sponsor research at VCU relating to the Technology. The research shall be
sponsored under one or more renewable agreements providing for the payment by
Allos of [ * ] by December 31, 1995. The terms of such research agreement(s)
shall be those contained in the standard research agreement used by VCU, except
that the research agreement shall provide that inventions made in the course of
the research funded by Allos and related to Allosteric Modifiers of Hemoglobin
licensed to Allos under this agreement will be licensed to Allos as part of the
Technology licensed under this agreement. If VCU declines to enter into
agreement(s) containing such terms, Allos shall not be obligated by this
agreement to sponsor such research.

2.2 CIT possesses two (2) disclosures of technology developed by Donald J.
Abraham et al. related to Allosteric Modifiers of Hemoglobin, CIT Case #538 and
Addition of Hydrophobic Anesthetics and Hydrophobic Compounds to Allosteric
Effectors of Hemoglobin, CIT Case #569 (Appendices A and B attached).
Hereafter, these new disclosures are referred to as the New Technology (the New
Technology). The New Technology was developed pursuant to Section 3 of the
Agreement, Funding of Research. Although the New Technology may not be included
in any claim of a U.S. Patent licensed to Allos, CIT and Allos agree to include
this New Technology as part of the Technology.

3  Allos shall within sixty (60) days from the end of each Allos fiscal year,
deliver to CIT a report citing jobs in Allos created and/or retained, revenues
generated, costs saved, capital investment and capital obtained related to the
Technology.

4  All terms in this Amendment shall be as defined in the Agreement.

*CONFIDENTIAL TREATMENT
      REQUESTED
<PAGE>   2

5  The Agreement, as amended by this Amendment, represents the entire
understanding between the parties and supersedes all other agreements or
amendments, expressed or implied, between the parties concerning the Technology.

6  The Agreement or this Amendment may be altered only in writing signed by
both parties.

ALLOS THERAPEUTICS, INC.

/s/ STEPHEN J. HOFFMAN
--------------------------------------
Title: President
Date:  4/23/95

CENTER FOR INNOVATIVE TECHNOLOGY

/s/ ROBERT G. TEMPLIN, JR.
--------------------------------------
Robert G. Templin, Jr.
President
Date: 2-14-95

VIRGINIA COMMONWEALTH UNIVERSITY

/s/ ROBERT GARRISON
--------------------------------------
Title: Director Tech Transfer
Date:  2/1/95

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}]]